You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameColestipol
Accession NumberDB00375  (APRD00884)
TypeSmall Molecule
GroupsApproved
DescriptionHighly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels. [PubChem]
Structure
Thumb
Synonyms
Colestipolum
Copolymer of bis(2-aminoethyl)amine and 2-(chloromethyl)oxirane
Epichlorohydrin-tetraethylenepentamine polymer
External Identifiers
  • U 26597 A
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ColestidTablet1 g/1OralPharmacia And Upjohn Company Llc1994-07-19Not applicableUs
ColestidGranule, for suspension5 g/5gOralPharmacia And Upjohn Company Llc1977-04-04Not applicableUs
Colestid GranulesGranule5 gOralPfizer Canada Inc1985-12-31Not applicableCanada
Colestid Orange GranulesGranule5 gOralPfizer Canada Inc1995-12-31Not applicableCanada
Colestid Tablets 1 GTablet1 gOralPfizer Canada Inc1995-12-31Not applicableCanada
Colestipol HydrochlorideTablet1 g/1OralPhysicians Total Care, Inc.2007-02-28Not applicableUs
Colestipol HydrochlorideTablet1 g/1OralCarilion Materials Management1994-07-19Not applicableUs
Colestipol HydrochlorideTablet1 g/1OralGreenstone LLC1994-07-19Not applicableUs
Colestipol HydrochlorideGranule, for suspension5 g/5gOralGreenstone LLC1977-04-04Not applicableUs
Flavored ColestidGranule, for suspension5 g/7.5gOralPharmacia And Upjohn Company Llc1977-04-04Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Colestipol HydrochlorideTablet, film coated1 g/1OralImpax Generics2006-10-24Not applicableUs
Colestipol HydrochlorideSuspension5 g/1OralImpax Generics2006-05-02Not applicableUs
Colestipol HydrochlorideSuspension5 g/1OralImpax Generics2006-05-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CholestabylNot Available
LestidPfizer
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Colestipol hydrochloride
37296-80-3
ThumbNot applicableDBSALT001058
Categories
UNIIK50N755924
CAS number26658-42-4
WeightAverage: 281.826
Monoisotopic: 281.19823825
Chemical FormulaC11H28ClN5O
InChI KeyGMRWGQCZJGVHKL-UHFFFAOYSA-N
InChI
InChI=1S/C8H23N5.C3H5ClO/c9-1-3-11-5-7-13-8-6-12-4-2-10;4-1-3-2-5-3/h11-13H,1-10H2;3H,1-2H2
IUPAC Name
(2-aminoethyl)[2-({2-[(2-aminoethyl)amino]ethyl}amino)ethyl]amine; 2-(chloromethyl)oxirane
SMILES
ClCC1CO1.NCCNCCNCCNCCN
Pharmacology
IndicationFor use, as adjunctive therapy to diet, for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet.
Structured Indications
PharmacodynamicsCholesterol is the major, and probably the sole precursor of bile acids. During normal digestion, bile acids are secreted via the bile from the liver and gall bladder into the intestines. Bile acids emulsify the fat and lipid materials present in food, thus facilitating absorption. A major portion of the bile acids secreted is reabsorbed from the intestines and returned via the portal circulation to the liver, thus completing the enterohepatic cycle. Only very small amounts of bile acids are found in normal serum. Colestipol hydrochloride binds bile acids in the intestine forming a complex that is excreted in the feces. This nonsystemic action results in a partial removal of the bile acids from the enterohepatic circulation, preventing their reabsorption. Since colestipol hydrochloride is an anion exchange resin, the chloride anions of the resin can be replaced by other anions, usually those with a greater affinity for the resin than the chloride ion.
Mechanism of actionColestipol is a non-absorbed, lipid-lowering polymer that binds bile acids in the intestine, impeding their reabsorption. As the bile acid pool becomes depleted, the hepatic enzyme, cholesterol 7-(alpha)-hydroxylase, is upregulated, which increases the conversion of cholesterol to bile acids. This causes an increased demand for cholesterol in the liver cells, resulting in the dual effect of increasing transcription and activity of the cholesterol biosynthetic enzyme, hydroxymethyl-glutaryl-coenzyme A (HMG-CoA) reductase, and increasing the number of hepatic low-density lipoprotein (LDL) receptors. These compensatory effects result in increased clearance of LDL cholesterol (LDL-C) from the blood, resulting in decreased serum LDL-C levels. Serum triglyceride levels may increase or remain unchanged. The end result is increased clearance of LDL-cholesterol from the blood with decreased serum LDL-cholesterol.
TargetKindPharmacological actionActionsOrganismUniProt ID
Bile acidsGroupyes
binder
Humannot applicabledetails
Related Articles
AbsorptionNot absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot applicable (not hydrolyzed by digestive enzymes and not absorbed).
Metabolism

Not applicable (not hydrolyzed by digestive enzymes and not absorbed).

Route of eliminationColestipol hydrochloride binds bile acids in the intestine forming a complex that is excreted in the feces. In humans, less than 0.17% of a single 14C-labeled colestipol hydrochloride dose is excreted in the urine when given following 60 days of chronic dosing of 20 grams of colestipol hydrochloride per day. The increased fecal loss of bile acids due to colestipol hydrochloride administration leads to an increased oxidation of cholesterol to bile acids.
Half lifeNot Available
ClearanceNot Available
ToxicityOral LD50 in rats is > 1000 mg/kg. Symptoms of overdose may include eye irritation, constipation, abdominal cramps, nausea, vomiting, diarrhea, and hypersensitivity. However, as colestipol is not absorbed, the risk of systemic toxicity is low.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneColestipol can cause a decrease in the absorption of 16-Bromoepiandrosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
19-norandrostenedioneColestipol can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
4-AndrostenedioneColestipol can cause a decrease in the absorption of 4-Androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
5-androstenedioneColestipol can cause a decrease in the absorption of 5-androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
AceclofenacColestipol can cause a decrease in the absorption of Aceclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcenocoumarolColestipol can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetovanilloneColestipol can cause a decrease in the absorption of Acetovanillone resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
AcetyldigitoxinColestipol can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Acetylsalicylic acidColestipol can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AdapaleneColestipol can cause a decrease in the absorption of Adapalene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneColestipol can cause a decrease in the absorption of Alclometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AldosteroneColestipol can cause a decrease in the absorption of Aldosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlfacalcidolThe serum concentration of Alfacalcidol can be decreased when it is combined with Colestipol.Approved, Nutraceutical
AmcinonideColestipol can cause a decrease in the absorption of Amcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmiodaroneThe bioavailability of Amiodarone can be decreased when combined with Colestipol.Approved, Investigational
AnecortaveColestipol can cause a decrease in the absorption of Anecortave resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
AnisodamineColestipol can cause a decrease in the absorption of Anisodamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
AntipyrineColestipol can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AnvirzelColestipol can cause a decrease in the absorption of Anvirzel resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
ApremilastColestipol can cause a decrease in the absorption of Apremilast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Colestipol.Approved
AzapropazoneColestipol can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
AzelastineColestipol can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BalsalazideColestipol can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
BeclomethasoneColestipol can cause a decrease in the absorption of Beclomethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Beclomethasone dipropionateColestipol can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
BendroflumethiazideColestipol can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BenoxaprofenColestipol can cause a decrease in the absorption of Benoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
BetamethasoneColestipol can cause a decrease in the absorption of Betamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Betulinic AcidColestipol can cause a decrease in the absorption of Betulinic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BezafibrateColestipol can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BromfenacColestipol can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BucillamineColestipol can cause a decrease in the absorption of Bucillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BudesonideColestipol can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BumetanideColestipol can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CalcidiolThe serum concentration of Calcidiol can be decreased when it is combined with Colestipol.Approved, Nutraceutical
CalcipotriolThe serum concentration of Calcipotriol can be decreased when it is combined with Colestipol.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Colestipol.Approved, Nutraceutical
CarprofenColestipol can cause a decrease in the absorption of Carprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved, Withdrawn
CastanospermineColestipol can cause a decrease in the absorption of Castanospermine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CelecoxibColestipol can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Colestipol.Approved
ChloroquineColestipol can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlorothiazideColestipol can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Colestipol.Withdrawn
ChlortetracyclineColestipol can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlorthalidoneColestipol can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Colestipol.Approved, Nutraceutical
Cholic AcidColestipol can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideColestipol can cause a decrease in the absorption of Ciclesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CiprofibrateColestipol can cause a decrease in the absorption of Ciprofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClobetasolColestipol can cause a decrease in the absorption of Clobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Clobetasol propionateColestipol can cause a decrease in the absorption of Clobetasol propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClocortoloneColestipol can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClofibrateColestipol can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClonixinColestipol can cause a decrease in the absorption of Clonixin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Colestipol.Approved
Cortisone acetateColestipol can cause a decrease in the absorption of Cortisone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CurcuminColestipol can cause a decrease in the absorption of Curcumin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
D-LimoneneColestipol can cause a decrease in the absorption of D-Limonene resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
DeferasiroxThe serum concentration of Deferasirox can be decreased when it is combined with Colestipol.Approved, Investigational
dehydroepiandrosterone sulfateColestipol can cause a decrease in the absorption of dehydroepiandrosterone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
DemeclocyclineColestipol can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DeslanosideColestipol can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Colestipol.Approved
DesoximetasoneColestipol can cause a decrease in the absorption of Desoximetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Desoxycorticosterone acetateColestipol can cause a decrease in the absorption of Desoxycorticosterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Desoxycorticosterone PivalateColestipol can cause a decrease in the absorption of Desoxycorticosterone Pivalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Vet Approved
DexamethasoneColestipol can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateColestipol can cause a decrease in the absorption of Dexamethasone isonicotinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
DiclofenacColestipol can cause a decrease in the absorption of Diclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
DicoumarolColestipol can cause a decrease in the absorption of Dicoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Colestipol.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Colestipol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Colestipol.Approved
DiflorasoneColestipol can cause a decrease in the absorption of Diflorasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiflunisalColestipol can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DifluocortoloneColestipol can cause a decrease in the absorption of Difluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DifluprednateColestipol can cause a decrease in the absorption of Difluprednate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DigitoxinColestipol can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DigoxinColestipol can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DihydrotachysterolThe serum concentration of Dihydrotachysterol can be decreased when it is combined with Colestipol.Approved
DiltiazemColestipol can cause a decrease in the absorption of Diltiazem resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxercalciferolThe serum concentration of Doxercalciferol can be decreased when it is combined with Colestipol.Approved
DoxycyclineColestipol can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Colestipol.Approved
DroxicamColestipol can cause a decrease in the absorption of Droxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DuvelisibColestipol can cause a decrease in the absorption of Duvelisib resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
E6201Colestipol can cause a decrease in the absorption of E6201 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
EbselenColestipol can cause a decrease in the absorption of Ebselen resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
EpirizoleColestipol can cause a decrease in the absorption of Epirizole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EquileninColestipol can cause a decrease in the absorption of Equilenin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
EquilinColestipol can cause a decrease in the absorption of Equilin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Colestipol.Approved, Nutraceutical
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Colestipol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Colestipol.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Colestipol.Approved
EstroneColestipol can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Colestipol.Approved
Etacrynic acidColestipol can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EtanerceptColestipol can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Colestipol.Approved
Ethyl biscoumacetateColestipol can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Colestipol.Approved
EtodolacColestipol can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EtofenamateColestipol can cause a decrease in the absorption of Etofenamate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EtofibrateColestipol can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Colestipol.Approved, Investigational
EtoricoxibColestipol can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Evening primrose oilColestipol can cause a decrease in the absorption of Evening primrose oil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
exisulindColestipol can cause a decrease in the absorption of exisulind resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
EzetimibeColestipol can cause a decrease in the absorption of Ezetimibe resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FenbufenColestipol can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FenofibrateColestipol can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FenoprofenColestipol can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FloctafenineColestipol can cause a decrease in the absorption of Floctafenine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
fluasteroneColestipol can cause a decrease in the absorption of fluasterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
FludrocortisoneColestipol can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluindioneColestipol can cause a decrease in the absorption of Fluindione resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
FlumethasoneColestipol can cause a decrease in the absorption of Flumethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
FlunisolideColestipol can cause a decrease in the absorption of Flunisolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FlunixinColestipol can cause a decrease in the absorption of Flunixin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
Fluocinolone AcetonideColestipol can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
FluocinonideColestipol can cause a decrease in the absorption of Fluocinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FluocortoloneColestipol can cause a decrease in the absorption of Fluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
FluorometholoneColestipol can cause a decrease in the absorption of Fluorometholone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneColestipol can cause a decrease in the absorption of Fluprednidene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
FluprednisoloneColestipol can cause a decrease in the absorption of Fluprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlurandrenolideColestipol can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlurbiprofenColestipol can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Fluticasone furoateColestipol can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Fluticasone PropionateColestipol can cause a decrease in the absorption of Fluticasone Propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FormestaneColestipol can cause a decrease in the absorption of Formestane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
FurosemideColestipol can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
GemfibrozilColestipol can cause a decrease in the absorption of Gemfibrozil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Colestipol.Approved
HE3286Colestipol can cause a decrease in the absorption of HE3286 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Colestipol.Withdrawn
HigenamineColestipol can cause a decrease in the absorption of Higenamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
HMPL-004Colestipol can cause a decrease in the absorption of HMPL-004 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
HydrochlorothiazideColestipol can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
HydrocortisoneColestipol can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
HydroflumethiazideColestipol can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IbuprofenColestipol can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IbuproxamColestipol can cause a decrease in the absorption of Ibuproxam resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
IcatibantColestipol can cause a decrease in the absorption of Icatibant resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IndapamideColestipol can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IndomethacinColestipol can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IndoprofenColestipol can cause a decrease in the absorption of Indoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
IsoxicamColestipol can cause a decrease in the absorption of Isoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
IstaroximeColestipol can cause a decrease in the absorption of Istaroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
KebuzoneColestipol can cause a decrease in the absorption of Kebuzone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
KetoprofenColestipol can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
KetorolacColestipol can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LeflunomideThe serum concentration of the active metabolites of Leflunomide can be reduced when Leflunomide is used in combination with Colestipol resulting in a loss in efficacy.Approved, Investigational
Levomefolic acidThe serum concentration of Levomefolic acid can be decreased when it is combined with Colestipol.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Colestipol.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Colestipol.Approved
LiothyronineThe serum concentration of Liothyronine can be decreased when it is combined with Colestipol.Approved, Vet Approved
LiotrixThe serum concentration of Liotrix can be decreased when it is combined with Colestipol.Approved
LisofyllineColestipol can cause a decrease in the absorption of Lisofylline resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
LomitapideColestipol can cause a decrease in the absorption of Lomitapide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LornoxicamColestipol can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LoxoprofenColestipol can cause a decrease in the absorption of Loxoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LumiracoxibColestipol can cause a decrease in the absorption of Lumiracoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Colestipol.Investigational
Magnesium salicylateColestipol can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolColestipol can cause a decrease in the absorption of Masoprocol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ME-609Colestipol can cause a decrease in the absorption of ME-609 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Meclofenamic acidColestipol can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Colestipol.Approved, Investigational
MedrysoneColestipol can cause a decrease in the absorption of Medrysone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Mefenamic acidColestipol can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MelengestrolColestipol can cause a decrease in the absorption of Melengestrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
MeloxicamColestipol can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
MesalazineColestipol can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Colestipol.Approved
MetamizoleColestipol can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Colestipol.Experimental
MethotrexateColestipol can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethyclothiazideColestipol can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethylprednisoloneColestipol can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
MetolazoneColestipol can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MinocyclineColestipol can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MizoribineColestipol can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
MometasoneColestipol can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Mycophenolate mofetilColestipol can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Colestipol.Approved
NabumetoneColestipol can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NafamostatColestipol can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NaftifineColestipol can cause a decrease in the absorption of Naftifine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NaproxenColestipol can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
NCX 1022Colestipol can cause a decrease in the absorption of NCX 1022 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NCX 4016Colestipol can cause a decrease in the absorption of NCX 4016 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NepafenacColestipol can cause a decrease in the absorption of Nepafenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NiacinColestipol can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Nutraceutical
Niflumic AcidColestipol can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NimesulideColestipol can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
NitroaspirinColestipol can cause a decrease in the absorption of Nitroaspirin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Colestipol.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Colestipol.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Colestipol.Approved
Oleoyl estroneColestipol can cause a decrease in the absorption of Oleoyl estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
OlopatadineColestipol can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OlsalazineColestipol can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OrgoteinColestipol can cause a decrease in the absorption of Orgotein resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
OuabainColestipol can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OxaprozinColestipol can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OxyphenbutazoneColestipol can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
OxytetracyclineColestipol can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ParamethasoneColestipol can cause a decrease in the absorption of Paramethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ParecoxibColestipol can cause a decrease in the absorption of Parecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Colestipol.Approved, Investigational
PhenindioneColestipol can cause a decrease in the absorption of Phenindione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhenprocoumonColestipol can cause a decrease in the absorption of Phenprocoumon resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhenylbutazoneColestipol can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PimecrolimusColestipol can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PiretanideColestipol can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PirfenidoneColestipol can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PiroxicamColestipol can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PolythiazideColestipol can cause a decrease in the absorption of Polythiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PrasteroneColestipol can cause a decrease in the absorption of Prasterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Colestipol.Approved
PrednicarbateColestipol can cause a decrease in the absorption of Prednicarbate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PrednisoloneColestipol can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PrednisoneColestipol can cause a decrease in the absorption of Prednisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PregnenoloneColestipol can cause a decrease in the absorption of Pregnenolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PropacetamolColestipol can cause a decrease in the absorption of Propacetamol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Colestipol.Approved, Investigational
PTC299Colestipol can cause a decrease in the absorption of PTC299 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
QuinethazoneColestipol can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RaloxifeneColestipol can cause a decrease in the absorption of Raloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ResveratrolColestipol can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
RimexoloneColestipol can cause a decrease in the absorption of Rimexolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RofecoxibColestipol can cause a decrease in the absorption of Rofecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational, Withdrawn
SalicylamideColestipol can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Salicylic acidColestipol can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
SalsalateColestipol can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SeratrodastColestipol can cause a decrease in the absorption of Seratrodast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SRT501Colestipol can cause a decrease in the absorption of SRT501 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
SulfasalazineColestipol can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulindacColestipol can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SuprofenColestipol can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Colestipol.Approved
TenoxicamColestipol can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TepoxalinColestipol can cause a decrease in the absorption of Tepoxalin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
TeriflunomideThe serum concentration of Teriflunomide can be decreased when it is combined with Colestipol.Approved
TetracyclineColestipol can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Thyroid, porcineThe serum concentration of Thyroid, porcine can be decreased when it is combined with Colestipol.Approved
Tiaprofenic acidColestipol can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TinoridineColestipol can cause a decrease in the absorption of Tinoridine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
TixocortolColestipol can cause a decrease in the absorption of Tixocortol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Tolfenamic AcidColestipol can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TolmetinColestipol can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TorasemideColestipol can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TranilastColestipol can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TriamcinoloneColestipol can cause a decrease in the absorption of Triamcinolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrichlormethiazideColestipol can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Trisalicylate-cholineColestipol can cause a decrease in the absorption of Trisalicylate-choline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ursodeoxycholic acidThe serum concentration of Ursodeoxycholic acid can be decreased when it is combined with Colestipol.Approved, Investigational
ValdecoxibColestipol can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational, Withdrawn
VancomycinThe therapeutic efficacy of Vancomycin can be decreased when used in combination with Colestipol.Approved
WarfarinColestipol can cause a decrease in the absorption of Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ZaltoprofenColestipol can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ZileutonColestipol can cause a decrease in the absorption of Zileuton resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
ZomepiracColestipol can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Food Interactions
  • Take with food.
References
Synthesis Reference

Lednicer, D. and Peery,C.Y.; US. Patent 3,803,237; April 9, 1974; assigned to The Upjohn Co.

General ReferencesNot Available
External Links
ATC CodesC10AC02
AHFS Codes
  • 24:06.04
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (53.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9221
Blood Brain Barrier+0.8825
Caco-2 permeable-0.5102
P-glycoprotein substrateSubstrate0.6506
P-glycoprotein inhibitor INon-inhibitor0.9435
P-glycoprotein inhibitor IINon-inhibitor0.956
Renal organic cation transporterNon-inhibitor0.6803
CYP450 2C9 substrateNon-substrate0.8931
CYP450 2D6 substrateNon-substrate0.7534
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateNon-inhibitor0.7178
CYP450 2C9 inhibitorNon-inhibitor0.8515
CYP450 2D6 inhibitorNon-inhibitor0.8411
CYP450 2C19 inhibitorNon-inhibitor0.7634
CYP450 3A4 inhibitorNon-inhibitor0.8919
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9404
Ames testAMES toxic0.9093
CarcinogenicityNon-carcinogens0.6451
BiodegradationNot ready biodegradable0.9346
Rat acute toxicity2.5333 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.508
hERG inhibition (predictor II)Non-inhibitor0.7601
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Impax laboratories inc
Packagers
Dosage forms
FormRouteStrength
Granule, for suspensionOral5 g/5g
GranuleOral5 g
TabletOral1 g
SuspensionOral5 g/1
TabletOral1 g/1
Tablet, film coatedOral1 g/1
Granule, for suspensionOral5 g/7.5g
Prices
Unit descriptionCostUnit
Colestid 90 5 gm Packets Box252.5USD box
Colestid 30 5 gm Packets Box81.11USD box
Colestid Flavored 5 gm/7.5 gm Packets3.29USD packet
Colestid 5 g Powder Packet1.04USD packet
Colestid Orange 5 g Powder Packet1.04USD packet
Colestid 1 gm tablet0.86USD tablet
Colestipol hcl 1 gm tablet0.66USD tablet
Colestid 5 gm Granules0.33USD gm
Colestid Flavored 5 gm Granules0.31USD gm
Colestid flavored granules0.3USD g
Colestid 1 g Tablet0.29USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5490987 No1993-02-132013-02-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
logP-2.206Not Available
Predicted Properties
PropertyValueSource
logP-2.5ChemAxon
pKa (Strongest Basic)9.81ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area88.13 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity56.04 m3·mol-1ChemAxon
Polarizability23.97 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as epoxides. These are compounds containing a cyclic ether with three ring atoms(one oxygen and two carbon atoms).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassEpoxides
Sub ClassNot Available
Direct ParentEpoxides
Alternative Parents
Substituents
  • Oxacycle
  • Secondary amine
  • Ether
  • Oxirane
  • Secondary aliphatic amine
  • Dialkyl ether
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Primary aliphatic amine
  • Amine
  • Alkyl halide
  • Alkyl chloride
  • Aliphatic heteromonocyclic compound
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

1. Bile acids
Kind
Group
Organism
Human
Pharmacological action
yes
Actions
binder
References
  1. LaRosa JC: The mechanism of action of lipid-lowering drugs. Angiology. 1982 Sep;33(9):562-76. [PubMed:7125296 ]
  2. Farmer JA, Gotto AM Jr: Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin Endocrinol Metab. 1995 Oct;9(4):825-47. [PubMed:8593127 ]
  3. Reiner Z: Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol. 2010 Feb;24(1):19-28. doi: 10.1111/j.1472-8206.2009.00764.x. Epub 2009 Aug 14. [PubMed:19682080 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23